A Multicenter, Open-Label, Single-Arm, Phase II Trial to Evaluate the Efficacy and Safety of Geptanolimab (GB226) in the Treatment of Patients (pts) with Programmed Cell Death Ligand 1 (Pd-L1)–positive Recurrent or Metastatic Cervical Cancer, for Whom Prior Platinum-Containing Chemotherapy Has Failed.
JOURNAL OF CLINICAL ONCOLOGY（2023）
Key words
PD-1 and PD-L1
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined